Author:
Klesiewicz Karolina,Karczewska Elżbieta,Nowak Paweł,Skiba-Kurek Iwona,Sito Edward,Pańczyk Katarzyna,Koczurkiewicz Paulina,Żelaszczyk Dorota,Pękala Elżbieta,Waszkielewicz Anna M.,Budak Alicja,Marona Henryk,Gunia-Krzyżak Agnieszka
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology
Reference20 articles.
1. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19:1–5.
2. Konturek SJ, Konturek PC, Konturek JW, Plonka M, Czesnikiewicz-Guzik M, Brzozowski T, Bielanski W. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J Physiol Pharmacol. 2006;57:29–50.
3. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, France: International Agency for Research on Cancer; 1994. Vol. 61.
4. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.
5. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013;4:43–6.